Global ACT deal closes
This article was originally published in The Tan Sheet
Executive Summary
Chattem announces May 29 the closing of an agreement to acquire the rights to anti-cavity mouthwash ACT in Western Europe together with worldwide trademark rights for $4.1 mil. and assumed liabilities. The Chattanooga, Tenn.-based firm announced the agreement May 7 after the European Commission approved it (1"The Tan Sheet" May 14, 2007, In Brief). Chattem acquired ACT and other brands in January 2007 as Johnson & Johnson divested brands in connection with its Pfizer Consumer Healthcare purchase (2"The Tan Sheet" Feb. 19, 2007, p. 10)...
You may also be interested in...
Chattem’s ACT goes global
The Chattanooga, Tenn.-based firm announces an agreement May 7 to acquire the Western Europe rights to ACTas well as worldwide trademark rights from Johnson & Johnson for $4.1 mil. plus certain assumed liabilities. The European Commission approved the transaction and the deal is expected to close in late May. J&J is divesting ACT as a condition of the EC's approval of J&J's Pfizer Consumer Healthcare acquisition and "certain regulatory requirements in connection with the acquisition in Greece," the firm says. Chattem acquired ACT and five other OTC brands from J&J/Pfizer in January 2007 (1"The Tan Sheet" Feb. 19, 2007, p. 10)...
Chattem Hopes Brands Acquired From J&J Offset Cool Sales Of Pro-Therapy
For 2007, Chattem expects sales of products recently acquired from Johnson & Johnson to rival its existing "big three," of Gold Bond skin care, Icy Hot topical analgesics and Selsun medicated shampoos
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.